Farsight Medical Technology (Shanghai) Co., Ltd.
- Biotech or pharma, therapeutic R&D
Farsight Medical Technology (Shanghai), a China-based biotech company, focuses on cyclophilin-related signaling pathway disorders and developing innovative therapies for unmet clinical needs.
Our first-in-class drug RN-0001 targets ischemia reperfusion and inflammation induced organ injuries. Completed Phase I and IIa trials demonstrate its safety and efficacy in treating Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). Additionally, a Phase II trial for Acute Pancreatitis has been approved by China’s Center for Drug Evaluation and will commence soon.
Beyond RN-0001, we have developed selective cyclophilin inhibitor series with preclinical candidates for diverse diseases, including Drug Induced Liver Injury, Alcoholic Liver Disease, Ischemic Stroke, Amyotrophic Lateral Sclerosis, Parkinson’s Disease, Dry Eye Disease, Periodontitis, Psoriasis, Atopic Dermatitis, Inflammatory Bowel Disease, Rheumatoid Arthritis, HBV&HDV etc.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}